Background-The circulating levels of secretory nonpancreatic type II phospholipase A 2 (sPLA 2 ) are increased in various chronic inflammatory diseases and the increase in the levels correlates with the disease severity. sPLA 2 may possibly play a role in atherogenesis and is highly expressed in atherosclerotic arterial walls that are known to have inflammatory features. Thus, this study prospectively examined whether circulating levels of sPLA 2 may have a significant risk and prognostic values in patients with coronary artery disease (CAD). Methods and Results-Plasma levels of sPLA 2 were measured in 142 patients with CAD and in 93 control subjects by a radioimmunoassay. The sPLA 2 levels had a significant and positive relations with serum levels of C-reactive protein, a marker of systemic inflammation, and with the number of the traditional coronary risk factors associated with individuals. Multivariate logistic regression analysis showed that higher levels of sPLA 2 (Ͼ246 ng/dL; 75th percentile of sPLA 2 distribution in controls) were a significant and independent risk factor for the presence of CAD. In multivariate Cox hazard analysis, the higher levels of sPLA 2 were a significant predictor of developing coronary events (ie, coronary revascularization, myocardial infarction, coronary death) during a 2-year follow-up period in patients with CAD independent of other risk factors, including CRP levels, an established inflammatory predictor. Conclusions-The increase in circulating levels of sPLA 2 is a significant risk factor for the presence of CAD and predicts clinical coronary events independent of other risk factors in patients with CAD; these results may reflect possible relation of sPLA 2 levels with inflammatory activity in atherosclerotic arteries. (Circulation. 1999;100:1280-1284.)
P
hospholipases A 2 (PLA 2 ) are ubiquitous enzymes that hydrolyze the sn-2-acyl bond of phospholipids of cell membrane and lipoproteins and yield free fatty acids and lysophospholipids, precursors of various proinflammatory lipid mediators including leukotrienes, eicosanoids, prostaglandins, and platelet-activating factors. [1] [2] [3] Several studies showed that secretory nonpancreatic type II phospholipase A 2 (sPLA 2 ) might importantly contribute to the pathogenesis of various inflammatory diseases. 2, 3 Recently, sPLA 2 was found to be highly expressed in human atherosclerotic arterial walls, 4 -6 where the inflammatory process is known to have a pathogenetic role. [7] [8] [9] The lipid products generated through sPLA 2 and their related products, including modified LDLs, participate in the development of atherosclerosis and play a significant role in the pathogenesis of coronary artery disease (CAD). 8 -12 There is growing evidence 2, 3, 13, 14 that the circulating levels of sPLA 2 are increased in various inflammatory diseases and that the levels reflect severity of these diseases, including rheumatic arthritis, inflammatory bowel diseases, and sepsis. Thus, it is expected that the circulating levels of sPLA 2 may also be increased in patients with CAD. In this study, we prospectively examined whether the circulating levels of sPLA 2 may have a significant risk and prognostic values in patients with CAD.
Methods

Study Patients
This study enrolled 196 consecutive patients with CAD who underwent elective and diagnostic cardiac catheterization for chest pain or ischemic changes in ECG in Kumamoto University Hospital. The patients with CAD who were admitted for the planned revascularization therapy were not eligible for this study. All patients had angiographic documentation of organic stenosis of Ͼ70% of at least one major coronary artery. Forty-nine patients were excluded because they had one of the following exclusion criteria: myocardial infarction, major surgery and trauma, and serious infectious diseases within previous 4 weeks; malignancies; and chronic inflammatory diseases, including rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease. Ultimately, 147 (75%) of the 196 patients were included in this study. Patients' characteristics are shown in Table 1 .
This study also enrolled 124 consecutive control subjects who underwent cardiac catheterization for atypical chest pain during the same study period as the patients with CAD. These control subjects were studied to evaluate sPLA 2 as a risk factor differing between patients with CAD and non-CAD patients. The control subjects had angiographically normal coronary arteries (Ͻ10% stenosis), normal left ventriculography, and no clinical evidence of coronary artery spasm and syndrome X. Of these subjects, this study finally included 93 age-and sex-matched control subjects who did not have any of the same exclusion criteria as described above for the patients with CAD. Written informed consent was obtained from all patients and subjects before the study. This study was in agreement with the guidelines approved by the ethics committee at our institution.
Biochemical Measurements
Venous blood was taken from all of the study patients and control subjects after an overnight fast. Blood samples, anticoagulated with EDTA or citrate, were immediately centrifuged at 3000 rpm at 4°C for 10 minutes. The plasma was aliquoted and stored at Ϫ80°C until analyzed. Levels of immunoreactive sPLA 2 in EDTA-plasma were measured by a radioimmunoassay using a monoclonal antibody developed against membrane-associated PLA 2 , which was purified from human spleen and was identical with type IIA PLA 2 purified from rheumatoid arthritic synovial fluid (Shionogi Pharmaceutical Ltd., Osaka, Japan). 15, 16 This monoclonal antibody had no detectable cross-reactivity with human pancreatic PLA 2 (type IB). 14, 15 The radioimmunoassay gave a linear response in a range from 78 to 5000 ng/dL of sPLA 2 . 14, 15 The interassay and intra-assay coefficients of variation were Ͻ8%. 14, 15 The plasma levels of the immunoreactive sPLA 2 had a significant correlation with the calcium-dependent PLA 2 activity in the citrated plasma (ϭ0.923, PϽ0.0001, nϭ88 by Spearman's rank correlation test), a result which is compatible with that in previous reports. 13, 14 Serum levels of C-reactive protein (CRP) were measured in all of the control subjects and the patients with CAD using an N Latex CRP immunodetection kit (Dade Behring). 14, 15 Serum levels of total cholesterol, triglycerides, and HDL-cholesterol were measured by the enzymatic methods, 17 and LDL-cholesterol levels were calculated as previously described. 17 
Follow-Up Study
After laboratory samples and catheterization data were obtained, the 147 patients with CAD (1-vessel disease, 70 patients; 2-vessel disease, 34 patients; three-vessel disease, 27 patients; left main coronary stenosis, 16 patients) were followed up every month in hospital or with a clinic visit for a maximum of 24 months or until occurrence of one of the following clinical coronary events: recurrent or refractory angina pectoris requiring coronary revascularization by PTCA or CABG, nonfatal myocardial infarction, and cardiac death. Time from the day when blood sampling was performed to first coronary event was prospectively evaluated. Diagnosis of myocardial infarction was made by chest pain, appearance of new Q wave on the ECG, and elevation of creatine kinase enzyme to more than twice the upper limit of normal. Cause of death was determined from hospital records. For the study, revascularization therapy based only on angiographic data were not counted as a coronary event. All of the patients received standardized medical therapy. The patients with high extent of CAD (3-vessel disease or left main coronary stenosis) who were included in this study were also followed up without revascularization therapy immediately after the inclusion because of diffuse peripheral CAD, a high risk with the procedure, previous CABG or repeated PTCA, or unwillingness for the revascularization therapy. The attending physician and interventional cardiologists independent of this prospective study decided the need for and timing of revascularization.
Statistical Analysis
Because sPLA 2 levels were not distributed normally, results of sPLA 2 levels are expressed as median and range (25th and 75th percentiles) and nonparametric analyses were used. Mann-Whitney U test was used to evaluate difference in sPLA 2 levels between the 2 groups. Spearman's rank correlation test was used for relations of sPLA 2 levels with CRP levels and number of the coronary risk factors associated with individuals. To evaluate sPLA 2 levels as an independent risk factor differing between the patients with CAD and the control subjects, forward, stepwise, multiple logistic regression analysis was performed using the following factors as categorical covariates: smoking history (defined as smoking at least 10 cigarettes per day for Ն10 years), hypertension (Ն140/90 mm Hg or requiring antihypertensive medication), diabetes mellitus (according to World Health Organization criteria, 18 hypercholesterolemia (Ն220 mg/dL or the use of lipid-lowering medications), high LDL-cholesterol (Ն130 mg/dL), low HDL-cholesterol (Ͻ35 mg/dL), and high CRP levels (Ͼ0.48 mg/dL, 90th percentile of the distribution of the CRP levels in the control subjects). Kaplan-Meier method (log-rank test) was applied in survival analysis according to the levels of sPLA 2 . The predictive value for coronary events during the follow-up period was assessed by Cox proportional hazard analysis. The multivariate Cox analysis always included the following factors as categorical covariates: sPLA 2 levels, stenosis of the left main coronary artery, number of coronary arteries with stenosis, low left ventricular ejection fraction (LVEF) on baseline left ventriculography (Ͻ 50%), age (Ն70 years), sex (male), smoking history, hypertension, diabetes mellitus, hypercholesterolemia, high LDL-cholesterol, and low HDL-cholesterol. Cutoff point (246 ng/dL) between higher and lower levels of sPLA 2 was arbitrarily defined as 75th percentile of the distribution of the sPLA 2 levels in the control subjects. In Cox hazard model and Kaplan-Meier analyses, sPLA 2 levels were divided into tertiles that were based on 90th and 75th percentiles of the distribution of the sPLA 2 levels in the control subjects. On scoring the number of coronary arteries with stenosis, stenosis of the left main coronary artery was counted as 2-vessel disease. Mean values of continuous variables with normal distribution and frequencies among subgroups were compared by unpaired t test and 2 analysis, respectively. Statistical significance was defined as PϽ0.05. The analyses were performed partly using SPSS Professional Statistics 6.1 for the Macintosh (SPSS Japan Inc). 
Results
sPLA 2 as a Coronary Risk Factor
The distribution of the levels of sPLA 2 immunoreactivity in patients with CAD was skewed and shifted to lower levels with a median level of 286 (218 and 386) ng/dL, which was significantly higher than that in control subjects (191 [154 and 246] ng/dL) (PϽ0.0001). The levels of sPLA 2 had a significant and positive correlation with CRP levels ( Figure 1 ). As shown in Figure 2 , the levels of sPLA 2 were significantly related with the number of the traditional coronary risk factors associated with individuals. There was no significant association of higher sPLA 2 levels (Ͼ246 ng/dL, 75th percentile of the sPLA 2 distribution in controls) with each of the traditional coronary risk factors (age Ն70 years, smoking history, diabetes mellitus, hypertension, hypercholesterolemia, and low HDL-cholesterol).
The patients with CAD had significantly lower HDL-cholesterol levels, higher LDL-cholesterol levels, higher CRP levels, higher rates of diabetes mellitus and hypertension, and higher sPLA 2 levels compared to control subjects (Table 1 ). In multiple logistic regression analysis with forward stepwise selection, the higher levels of sPLA 2 (Ͼ246 ng/dL), diabetes mellitus, and hypertension were the variables differing significantly and independently between the patients with CAD and the control subjects, as shown in Table 2 
sPLA 2 as a Predictor of Coronary Events in Patients with CAD
All of the patients received the standard medical therapy consisting of a combination of calcium channel blockers (used in 82% of patients), ␤-blockers (41%), nitrates (70%), angiotensin-converting enzyme inhibitor (38%), aspirin (93%), and lipid-lowering drugs (34%) during the follow-up study. Seven patients with unstable angina and high extent of CAD had intravenous infusion of heparin and nitrates for several days (2 to 7 days) after the inclusion. Only 5 patients with CAD were lost to follow-up. The remaining 142 patients with CAD were followed for a mean duration of 17.2 months (range, 0.5 to 24 months). The patients with higher levels of sPLA 2 (Ͼ246 ng/dL, 95 patients) had 41 coronary events (14 PTCA, 13 CABG, 5 myocardial infarction, 9 coronary death) during the follow-up period, whereas the patients with lower levels (Յ246 ng/dL, 47 patients) had 7 events (1 PTCA, 5 CABG, 1 coronary death) (PϽ0.01 in frequencies of coronary events between the 2 subgroups). There was no significant difference in the rates of each of the drugs used between the patients with and without coronary events during the follow-up period (data not shown). Kaplan-Meier analysis demonstrated a significantly higher probability of developing the clinical coronary events in the patients with the higher levels of sPLA 2 than those with the lowest levels, as shown in Figure 3 . In univariate Cox proportional hazard model analysis, higher levels of sPLA 2 ( Forward, stepwise, multiple logistic regression analysis was performed using the following factors as categorical covariates: sPLA 2 Ͼ246 ng/dL, smoking history, hypertension, diabetes mellitus, hypercholesterolemia, high levels of LDL-cholesterol, low levels of HDL-cholesterol, and high CRP levels (Ͼ0.48 mg/dL).
predictor of the clinical coronary events in patients with CAD. Multivariate Cox proportional hazard analysis showed that only higher levels of sPLA 2 were a significant predictor of the coronary events independent of the traditional risk factors, left main coronary stenosis, 3-vessel disease, and low LVEF (Table 3) . When CRP was added to the covariates in multivariate Cox analysis, sPLA 2 but not CRP remained a significant predictor of the future coronary events independent of the other risk factors (Odds, 3.3; 95% CI, 1.3 to 9.2; Pϭ0.01 highest versus lowest tertile of sPLA 2 levels; odds, 1.3; 95% CI; 0.67 to 2.6; Pϭ0.43, higher versus lower CRP levels). The inclusion of previous myocardial infarction and unstable angina at baseline examination into the covariates in the multivariate Cox analysis did not significantly affect the predictive value of higher sPLA 2 levels (highest versus lowest tertile of sPLA 2 levels, after addition of previous myocardial infarction into the covariates: Odds, 3.5; 95% CI, 1.4 to 8.3; Pϭ0.006, after addition of unstable angina into the covariates: odds, 3.3; 95% CI, 1.4 to 8.1; Pϭ0.008). Previous myocardial infarction and revascularization therapy before inclusion in this study, presence of unstable angina at baseline examination, low LVEF, and other traditional coronary risk factors did not have significant predictive value for coronary events in the study patients with CAD in either univariate or multivariate Cox proportional hazard analysis.
Discussion
The study demonstrated that the increase in plasma levels of sPLA 2 was an independent risk factor for the presence of CAD and that the increase in the levels predicted the development of clinical coronary events in patients with CAD. There is increasing evidence that atherosclerosis is an inflammatory disease that develops in response to the coronary risk factors. [7] [8] [9] 12 In this context, the present study further showed that the circulating levels of sPLA 2 were significantly correlated with the levels of CRP, a marker of systemic inflammation, and with the number of the traditional coronary risk factors associated with individuals. These imply that the increase in sPLA 2 levels in patients with CAD may reflect the inflammatory activity in the development of atherosclerosis. sPLA 2 may be one of the inflammatory markers, but sPLA 2 is a better inflammatory predictor of coronary events than CRP, a well established inflammatory prognostic marker because sPLA 2 but not CRP remained a significant and independent predictor in the multivariate Cox hazard analysis when addition of both factors into the covariates. sPLA 2 is shown to be induced in vascular cells by cytokines such as interleukin-1 and tumor necrosis factor-␣, 2,3,19 -21 which abundantly exist in atherosclerotic arterial walls and have crucial roles in the inflammatory and immunological features in atherosclerotic development. 7, 9, 11 These cytokines could stimulate synthesis of sPLA 2 in the atherosclerotic arterial walls and release into circulation, resulting in the elevation of the sPLA 2 levels in patients with CAD.
The lipid products generated through PLA 2 and their related products, such as lysophosphatidylcholine and modified LDL, are proatherogenic and proinflammatory 2,3,10,11 and they activate vascular cells to produce plasminogen activators (PA), PA inhibitor-1, adhesion molecules, various proatherogenic cytokines and growth factors, and oxygen free radicals, 10, [22] [23] [24] leading to atherothrombotic development and plaque instability in the atherosclerotic arterial walls. 8, 9, 12, 25 This atherothrombogenic role of sPLA 2 may result in the association of the increased levels of sPLA 2 with the high frequency of future coronary evens in patients with CAD, as observed in our study. The causative role of sPLA 2 levels in human plaque unstabilization is now under investigation in our laboratory. Kaplan-Meier curves comparing the probability of developing coronary events according to the sPLA 2 levels during follow-up period maximally for 24 months after enrollment in 142 patients with CAD. End points were revascularization (PTCA and CABG) due to recurrent and refractory angina pectoris, nonfatal myocardial infarction, and cardiac death. Time to first coronary event was prospectively evaluated. sPLA 2 levels were divided into tertiles based on 90th and 75th percentiles (366 and 246 ng/dL, respectively) of the distribution of sPLA 2 levels in control subjects. nϭ37, 58, and 47 in the highest (Ͼ366 ng/dL), the second (between 247 and 366 ng/dL), and the lowest (Յ246 ng/dL) tertile, respectively. sPLA 2 levels were divided into tertiles based on 90th and 75th percentiles (366 and 246 ng/dL, respectively) of the distribution of sPLA 2 levels in control subjects. sPLA 2 levels, stenosis of left main coronary artery, number of diseased coronary arteries, age (Ն70 y), male sex, histories of smoking, diabetes mellitus, and hypertension, hypercholesterolemia, high levels of LDL-cholesterol, low levels of HDL-cholesterol, and low LV ejection fraction were included as categorical covariates on multivariate analysis.
Recent reports have demonstrated that the increase in levels of CRP was associated with CAD. 26, 27 CRP is hepatically derived and has an uncertain physiological role in atherosclerotic development and in CAD. sPLA 2 could be also one of acute phase reactants. 2, 3, 14, 15 However, unlike CRP, the lipid mediators produced through sPLA 2 and their related lipids in the arterial walls can stimulate T cells and macrophages to synthesize and release the proatherogenic and proinflammatory cytokines, 2, 3, [7] [8] [9] [10] [11] 28 which may in turn induce sPLA 2 production in the atherosclerotic arterial walls. 2,3,19 -21 These positive feedback mechanisms could amplify this sequence of events in the atherosclerotic arterial walls, thereby sPLA 2 present in the arterial walls may play an important role in the pathogenesis of CAD, not simply as a marker of inflammation.
This study showed that diabetes mellitus, hypertension, and high sPLA 2 levels were significant and independent variables differing between patients with CAD and the control subjects. However, in the present prospective study, only high sPLA 2 levels (but not other traditional coronary risk factors including diabetes and hypertension) had predictive values for coronary events. The lack of the predictive significance of diabetes and hypertension in the present prospective study may be partly explained by the modification of these traditional risk factors during the follow-up by medications and improvement of lifestyle. Our study also showed that extensive coronary diseases (left main coronary disease and 3-vessel disease) had weak but significant probability for clinical coronary events in the univariate analysis. However, presence of the extensive coronary diseases alone may not be related directly to the significant probability of coronary events, which will not necessarily be provoked at the sites of severe coronary stenosis on baseline angiograms. 25 Other associated risk factors may additionally contribute to the significant probability because the extensive coronary diseases did not remain significant in the multivariate analysis.
This study is limited by the small number of the studied patients. Also, a case-control study has cross-sectional nature and it may have inherent selection bias of cases and controls. A trial with specific inhibitors of sPLA 2 activity in a large number of study patients with homogeneous risk is required to assess the precise role of sPLA 2 in the pathogenesis of CAD.
In conclusion, high levels of sPLA 2 in the circulation have an independent risk factor for the presence of CAD and predict future coronary events in patients with CAD.
